Trial
NCT02439346
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bayer
Collaborators
—
Condition
Medical Oncology
Intervention
BAY1143269 tablet
Why stopped
Study stopped due to project prioritization
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-07